Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miguel Gil

Showing results (161-170 of 217) with videos related to

Pageof 22
Sort By:
Cancer Medicine|November 7, 2017
Pseudoprogression as an adverse event of glioblastoma therapyCarmen Balaña, Jaume Capellades, Estela Pineda, et al.
Veterinary World|January 20, 2025
Exploring the therapeutic potential of <i>Quercus ilex</i> acorn extract in papillomavirus-induced lesionsBeatriz Medeiros-Fonseca, Ana I Faustino-Rocha, Maria João Pires, et al.
Journal of Cardiac Surgery|January 4, 2020
Late management of the aortic root after repair of tetralogy of Fallot: A European multicentre studyVladimiro L Vida, Laura Torlai Triglia, Lorenza Zanotto, et al.
Epilepsia|March 1, 2014
Antiepileptic drug use in seven electronic health record databases in Europe: a methodologic comparisonMark C H de Groot, Markus Schuerch, Frank de Vries, et al.
The Oncologist|September 30, 2018
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent GlioblastomaAlba A Brandes, Miguel Gil-Gil, Frank Saran, et al.
Breast Cancer Research and Treatment|April 12, 2023
Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impactAmparo Garcia-Tejedor, Catalina Falo, Sergi Fernandez-Gonzalez, et al.
NPJ Breast Cancer|March 6, 2024
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapyTomás Pascual, Aranzazu Fernandez-Martinez, Yash Agrawal, et al.
Breast Cancer Research : BCR|May 11, 2025
Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trialAndrea Vethencourt, Eva M Trinidad, Eduard Dorca, et al.
Journal of Neuro-Oncology|November 28, 2017
Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastomaAndrés F Cardona, Leonardo Rojas, Beatriz Wills, et al.
JAMA Oncology|October 7, 2021
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical TrialAntonio Llombart-Cussac, José Manuel Pérez-García, Meritxell Bellet, et al.
Pageof 22

Showing results (161-170 of 217) with videos related to

Sort By:
Pageof 22
Cancer Medicine|November 7, 2017
Pseudoprogression as an adverse event of glioblastoma therapyCarmen Balaña, Jaume Capellades, Estela Pineda, et al.
Veterinary World|January 20, 2025
Exploring the therapeutic potential of <i>Quercus ilex</i> acorn extract in papillomavirus-induced lesionsBeatriz Medeiros-Fonseca, Ana I Faustino-Rocha, Maria João Pires, et al.
Journal of Cardiac Surgery|January 4, 2020
Late management of the aortic root after repair of tetralogy of Fallot: A European multicentre studyVladimiro L Vida, Laura Torlai Triglia, Lorenza Zanotto, et al.
Epilepsia|March 1, 2014
Antiepileptic drug use in seven electronic health record databases in Europe: a methodologic comparisonMark C H de Groot, Markus Schuerch, Frank de Vries, et al.
The Oncologist|September 30, 2018
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent GlioblastomaAlba A Brandes, Miguel Gil-Gil, Frank Saran, et al.
Breast Cancer Research and Treatment|April 12, 2023
Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impactAmparo Garcia-Tejedor, Catalina Falo, Sergi Fernandez-Gonzalez, et al.
NPJ Breast Cancer|March 6, 2024
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapyTomás Pascual, Aranzazu Fernandez-Martinez, Yash Agrawal, et al.
Breast Cancer Research : BCR|May 11, 2025
Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trialAndrea Vethencourt, Eva M Trinidad, Eduard Dorca, et al.
Journal of Neuro-Oncology|November 28, 2017
Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastomaAndrés F Cardona, Leonardo Rojas, Beatriz Wills, et al.
JAMA Oncology|October 7, 2021
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical TrialAntonio Llombart-Cussac, José Manuel Pérez-García, Meritxell Bellet, et al.
Pageof 22